A Peptide Containing T-Cell Epitopes of &amp;lt;i&amp;gt;Chlamydia trachomatis&amp;lt;/i&amp;gt; Recombinant MOMP Induces Systemic and Mucosal Antibody Responses in Mice

Taha, Murtada; Singh, Shree Ram; Hulett, Kara; Pillai, Shreekumar R.; Agee, R; Dennis, Vida A.

doi:10.4236/wjv.2011.14014

Cited by 8 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recombinant MOMP-278 (M278) was cloned as previously reported 15 and encapsulated in PLA-PEG nanoparticles using a modified water/oil/water double emulsion evaporation technique 16,17 and then lyophilized in the presence of 5% trehalose (as a stabilizer) to obtain encapsulated-M278 (PLA-PEG-M278). Phosphate buffered saline (PBS) was similarly encapsulated in PLA-PEG to serve as a negative control (PLA-PEG-PBS).…”

Section: Methodsmentioning

confidence: 99%

“…In the present study, we employed PLA-PEG as a delivery system for M278 15 , a C. trachomatis recombinant MOMP peptide, and hypothesized that encapsulation of M278 will provide for its sustained slow release to potentiate and bolster immune responses in mice. First, by in vitro studies we determined the physiochemical characteristics of encapsulated-M278 (size, zeta potential, morphology, absorbance and chemical compositions), encapsulation efficiency, release pattern, and toxicity to macrophages.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Poly(lactic acid)–poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice

Dixit

Singh

Yilma

et al. 2014

Nanomedicine: Nanotechnology, Biology and Medicine

Self Cite

View full text Add to dashboard Cite

PLA-PEG [poly (lactic acid)-poly (ethylene glycol)], a biodegradable copolymer, is underexploited for vaccine delivery although it exhibits enhanced biocompatibility and slow release immune-potentiating properties. We document here successful encapsulation of M278, a Chlamydia trachomatis MOMP (major outer membrane protein) peptide, within PLA-PEG nanoparticles by size (~73–100 nm), zeta potential (−16 mV), smooth morphology, encapsulation efficiency (~60%), slow release pattern, and non-toxicity to macrophages. Immunization of mice with encapsulated-M278 elicited higher M278-specific T-cell cytokines [Th1 (IFN-γ, IL-2), Th17 (IL-17)] and antibodies [Th1 (IgG2a), Th2 (IgG1, IgG2b)] compared to bare M278. Encapsulated-M278 mouse serum inhibited Chlamydia infectivity of macrophages, with a concomitant transcriptional down-regulation of MOMP, its cognate TLR2 and CD80 co-stimulatory molecule. Collectively, encapsulated-M278 potentiated crucial adaptive immune responses, which are required by a vaccine candidate for protective immunity against Chlamydia. Our data highlights PLA-PEG’s potential for vaccines, which resides in its slow release and potentiating effects to bolster immune responses.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Poly(lactic acid)–poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice

Dixit

Singh

Yilma

et al. 2014

Nanomedicine: Nanotechnology, Biology and Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…IgG2a . IgG1, Taha et al [29] proposed that rMOMP-278 immunization induced a mixed Th1/Th2 response, but with a bias to Th1 response, in contrast to that rMOMP predominantly induced Th2 response with the order of specific antibody production of IgG1 . IgG2b .…”

Section: Discussionmentioning

confidence: 99%

“…Safety concerns have led to other strategies for vaccine development that focus on epitope vaccines. Taha et al [29] selected a small gene fragment from MOMP containing T-cell epitopes (aa 278-370) and generated a recombinant MOMP peptide (rMOMP-278, 93 aa). They used rMOMP-278 to immunize mice and found that the rMOMP-278 induced higher responses for antigen-specific antibodies.…”

Section: Discussionmentioning

confidence: 99%

A multi-epitope vaccine based on <italic>Chlamydia trachomatis</italic> major outer membrane protein induces specific immunity in mice

Tu¹,

Hou²,

Wang³

et al. 2014

ABBS

View full text Add to dashboard Cite

We evaluated the immunogenicity and efficacy of a candidate vaccine comprising the major outer membrane protein (MOMP) multi-epitope of Chlamydia trachomatis. A short gene of multi-epitope derived from MOMP containing multiple T-and B-cell epitopes was artificially synthesized. The recombinant plasmid pET32a(1) containing codon optimized MOMP multi-epitope gene was constructed. Expression of the fusion protein Trx-His-MOMP multi-epitope in Escherichia coli was confirmed by sodium dodecyl sulfate -polyacrylamide gel electrophoresis and western blot analysis. Balb/c mice were inoculated with the purified fusion protein subcutaneously three times with 2-week intervals. Results showed that the MOMP multiepitope elicited not only strong humoral immune responses to C. trachomatis by generating significantly high levels of specific antibodies (IgG1 and IgG2a), but also a cellular immune response by inducing robust cytotoxic T lymphocyte responses in mice. Furthermore, the MOMP multiepitope substantially primed secretion of IFN-g, revealing that this vaccine could induce a strong Th1 response. Finally, the mice vaccinated with the MOMP multi-epitope displayed a reduction of C. trachomatis shedding upon a chlamydial challenge and an accelerated clearance of the infected C. trachomatis. In conclusion, the MOMP multiepitope vaccine may have the potentiality for the development of effective prophylactic and therapeutic vaccines against the C. trachomatis infection.

show abstract

“…Sera collected two weeks following the last immunization from the groups of mice were pooled and used to detect anti-rMOMPspecific antibody responses as previously described, 35,49 except that 5 µg/mL of purified rMOMP was used to coat plates in the present study. To determine antibody concentrations (titers), two-fold serial dilutions of serum were made and added to appropriate wells, followed by addition of either horseradish peroxidase-conjugated goat antimouse immunoglobulin (Ig) G, Ig2a, or IgG1 (Southern Biotech, Birmingham, AL, USA) antibody at a dilution of1:2000.…”

Section: Antibody Determinationmentioning

confidence: 99%

Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine

Fairley¹,

Singh²,

Yilma³

et al. 2013

IJN

View full text Add to dashboard Cite

Abstract:We recently demonstrated by in vitro experiments that PLGA (poly D, L-lactideco-glycolide) potentiates T helper 1 (Th1) immune responses induced by a peptide derived from the recombinant major outer membrane protein (rMOMP) of Chlamydia trachomatis, and may be a promising vaccine delivery system. Herein we evaluated the immune-potentiating potential of PLGA by encapsulating the full-length rMOMP (PLGA-rMOMP), characterizing it in vitro, and investigating its immunogenicity in vivo. Our hypothesis was that PLGA-rMOMP triggers Th1 immune responses in mice, which are desirable prerequisites for a C. trachomatis candidate nanovaccine. Physical-structural characterizations of PLGA-rMOMP revealed its size (approximately 272 nm), zeta potential (−14.30 mV), apparent spherical smooth morphology, and continuous slow release pattern. PLGA potentiated the ability of encapsulated rMOMP to trigger production of cytokines and chemokines by mouse J774 macrophages. Flow cytometric analyses revealed that spleen cells from BALB/c mice immunized with PLGA-rMOMP had elevated numbers of CD4+ and CD8+ T cell subsets, and secreted more rMOMP-specific interferon-gamma (Th1) and interleukin (IL)-12p40 (Th1/Th17) than IL-4 and IL-10 (Th2) cytokines. PLGA-rMOMP-immunized mice produced higher serum immunoglobulin (Ig)G and IgG2a (Th1) than IgG1 (Th2) rMOMP-specific antibodies. Notably, sera from PLGA-rMOMPimmunized mice had a 64-fold higher Th1 than Th2 antibody titer, whereas mice immunized with rMOMP in Freund's adjuvant had only a four-fold higher Th1 than Th2 antibody titer, suggesting primarily induction of a Th1 antibody response in PLGA-rMOMP-immunized mice. Our data underscore PLGA as an effective delivery system for a C. trachomatis vaccine. The capacity of PLGA-rMOMP to trigger primarily Th1 immune responses in mice promotes it as a highly desirable candidate nanovaccine against C. trachomatis.

show abstract

A Peptide Containing T-Cell Epitopes of <i>Chlamydia trachomatis</i> Recombinant MOMP Induces Systemic and Mucosal Antibody Responses in Mice

Abstract: ABSTRACT

Cited by 8 publications

References 26 publications

Poly(lactic acid)–poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice

Poly(lactic acid)–poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice

A multi-epitope vaccine based on <italic>Chlamydia trachomatis</italic> major outer membrane protein induces specific immunity in mice

Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine

Contact Info

Product

Resources

About

A Peptide Containing T-Cell Epitopes of &lt;i&gt;Chlamydia trachomatis&lt;/i&gt; Recombinant MOMP Induces Systemic and Mucosal Antibody Responses in Mice

Abstract: ABSTRACT

Cited by 8 publications

References 26 publications

Poly(lactic acid)–poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice

Poly(lactic acid)–poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice

A multi-epitope vaccine based on &lt;italic&gt;Chlamydia trachomatis&lt;/italic&gt; major outer membrane protein induces specific immunity in mice

Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine

Contact Info

Product

Resources

About

A Peptide Containing T-Cell Epitopes of <i>Chlamydia trachomatis</i> Recombinant MOMP Induces Systemic and Mucosal Antibody Responses in Mice

A multi-epitope vaccine based on <italic>Chlamydia trachomatis</italic> major outer membrane protein induces specific immunity in mice